Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Human Epidermal Growth Factor Receptor 2 (HER2)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04711252
What this trial is testing

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 1,370
Early research (Phase 1)Study completedNCT04040699
What this trial is testing

KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor

Who this might be right for
HER2 Positive Solid Tumor
Peking University 48
Early research (Phase 1)Study completedNCT00647114
What this trial is testing

Test V930/V932 in Patients With Cancers Expressing Human Epidermal Growth Factor Receptor 2 (HER-2) and/or Carcinoembryonic Antigen (CEA)(V930-003)(COMPLETED)

Who this might be right for
Cancer
Merck Sharp & Dohme LLC 41
Not applicableStudy completedNCT02032745
What this trial is testing

Genomic Signatures to Predict Treatment Response

Who this might be right for
Breast Neoplasms
Medical University of Graz 277
Not applicableActive Not RecruitingNCT05939128
What this trial is testing

A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA

Who this might be right for
Breast Cancer
AstraZeneca 625
Post-approval studies (Phase 4)Looking for participantsNCT05525767
What this trial is testing

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Who this might be right for
Solid Tumor
Hebei Medical University Fourth Hospital 75
Testing effectiveness (Phase 2)Study completedNCT03007992
What this trial is testing

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Johannes Gutenberg University Mainz 9
Large-scale testing (Phase 3)Study completedNCT01764022
What this trial is testing

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Who this might be right for
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Biocad 225
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339281
What this trial is testing

Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Li Huiping 68
Not applicableEnded earlyNCT04106167
What this trial is testing

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

Who this might be right for
Advanced Solid TumorLymphomaGastric Cancer+15 more
Fate Therapeutics 20
Not applicableLooking for participantsNCT07546695
What this trial is testing

Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study

Who this might be right for
Breast Cancer
University Hospital, Basel, Switzerland 600
Testing effectiveness (Phase 2)Looking for participantsNCT04329065
What this trial is testing

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
University of Washington 25
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Not applicableStudy completedNCT01777945
What this trial is testing

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 46
Testing effectiveness (Phase 2)Study completedNCT01855828
What this trial is testing

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Who this might be right for
Her2-Positive Breast Cancer
Yale University 50
Early research (Phase 1)Looking for participantsNCT07492628
What this trial is testing

Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma

Who this might be right for
Bladder CancerUrothelial CarcinomaMetastatic Urothelial Carcinoma+2 more
Beijing Biotech 42
Not applicableLooking for participantsNCT05792150
What this trial is testing

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

Who this might be right for
Female Breast Cancer
Women's Cancer Study Group GmbH 1,470
Testing effectiveness (Phase 2)Study completedNCT01736410
What this trial is testing

Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
HER 2 Positive Advanced Gastric Cancer
National Cancer Centre, Singapore 30
Early research (Phase 1)Not Yet RecruitingNCT07601620
What this trial is testing

Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer

Who this might be right for
HER2 + Breast Cancer
Shanghai Henlius Biotech 258
Next Page